Table 3.

Association between the MMP-8 rs11225395 polymorphism and cancer risk.

Comparison	Allele Model (T vs. C)			Homozygote Model (TT vs. CC)			Heterozygote Model (CT vs. CC)			Dominant Model (CT+TT vs. CC)			Recessive Model (TT vs. CC+CT)
(Number of Study)	OR (95% CI)	p	ph	OR (95% CI)	p	ph	OR (95% CI)	p	ph	OR (95% CI)	p	ph	OR (95% CI)		p	ph
Overall (15)	1.03(0.95,1.11)	0.46	0.02	1.01(0.85,1.20)	0.90	0.03	1.06(0.98,1.14)	0.14	0.13	1.04(0.93,1.16)	0.49	0.03	0.97(0.83,1.13)		0.70	0.05
Region
Asia (9)	0.97(0.89,1.07)	0.57	0.07	0.89(0.77,1.03)	0.12	0.18	0.97(0.88,1.07)	0.55	0.57	0.95(0.87,1.04)	0.26	0.34	0.89(0.77,1.02)		0.09	0.14
Others (6)	1.11(1.04,1.19)	<0.01	0.43	1.22(1.05,1.41)	0.01	0.39	1.21(1.07,1.36)	<0.01	0.43	1.21(1.08,1.35)	<0.01	0.45	1.09(0.96,1.24)		0.19	0.17
Cancer type
Bladder (3)	0.97(0.83,1.12)	0.67	0.29	0.85(0.61,1.17)	0.32	0.14	1.08(0.87,1.33)	0.49	0.84	1.02(0.84,1.25)	0.81	0.58	0.83(0.61,1.12)		0.22	0.15
Breast (4)	1.06(1.00,1.13)	0.07	0.20	1.04(0.78,1.37)	0.80	0.08	1.08(0.89,1.30)	0.43	0.08	1.07(0.86,1.31)	0.55	0.04	1.02(0.89,1.16)		0.79	0.25
Digestive System (3)	1.03(0.83,1.28)	0.78	0.05	0.99(0.79,1.24)	0.95	0.11	1.10(0.80,1.49)	0.57	0.07	1.09(0.79,1.51)	0.59	0.04	0.97(0.79,1.20)		0.80	0.30
Others (5)	1.07(0.83,1.39)	0.60	0.02	1.14(0.71,1.86)	0.58	0.05	1.01(0.74,1.37)	0.96	0.09	1.03(0.75,1.44)	0.84	0.04	1.08(0.65,1.79)		0.78	0.02
Sample Size
≤500 (5)	0.98(0.82,1.16)	0.80	0.20	0.87(0.60,1.27)	0.48	0.11	1.08(0.83,1.41)	0.56	0.46	1.02(0.79,1.31)	0.88	0.51	0.82(0.41,1.64)		0.57	<0.01
>500 (10)	1.03(0.95,1.12)	0.41	0.01	1.03(0.87,1.23)	0.71	0.04	1.05(0.93,1.18)	0.43	0.06	1.04(0.92,1.19)	0.52	<0.01	1.01(0.91,1.11)		0.86	0.44

OR: odds ratio. CI: confidence interval. p_h: p-value for between-study heterogeneity.